copies of ABL transcript indicate a high risk for relapse.
Regarding the other reported studies, Krauter et al 4 also used a similar real-time RT-PCR assay for the quantification of CBFb/ MYH11 transcripts, but failed to find any association with clinical response or relapse rate. More significantly, Marcucci et al 3 and Krauter et al 4 analyzed bone marrow samples from 16 patients with inv(16) AML enrolled on a German multicenter trial (AML HD93) for levels of CBFb/MYH11 fusion transcripts by real-time RT-PCR at diagnosis (n ¼ 14), during remission (n ¼ 10), and at relapse (n ¼ 6). The CBFb/MYH11 transcript copy number in each sample was normalized to copies of a different internal control housekeeping transcript (ie 18S instead of ABL). No difference in levels of CBFb/MYH11 fusion transcripts measured during intensification therapy was found between patients destined to relapse and those who maintained CCR. However, following completion of the entire chemotherapy program, patients who showed a CBFb/MYH11 copy number ratios 410 during CR had a significantly shorter relapse-free survival (P ¼ 0.002) and higher risk of relapse (P ¼ 0.05) than patients with copy numbers o10.
Taken together, the available data generally support the feasibility and utility of sensitive detection and quantification of CBFb/MYH11 transcripts by real-time RT-PCR in the follow-up of patients with inv(16)-positive AML. The data from Guerrasio et al 1 confirm our earlier conclusion 2 that it is possible to determine in remission samples a CBFb/MYH11 transcript copy number threshold above which relapse occurs and below which continuous CR is likely. Further studies should pinpoint the threshold value more precisely. The interesting data reported by Martinelli et al in Leukemia, 1 recalcutated from the article recently published in Blood, 2 are entirely consistent with ours 3 and with the previous ones published in Leukemia by Marcucci et al. 4 In all the above papers, authors concluded that a threshold level of CBFbeta/ MYH11 transcript copy number able to distinguish patients in clinical remission (CR) with high and low risk of relapse could be defined. However, two crucial issues remain unsettled so far: (1) the absolute copy number of the threshold level that varied slightly but significantly among the above labs; and (2) the timing of bone marrow sampling during CR most useful in predicting patient clinical outcome. With regard to the first issue, many variables of CBFbeta/MYH11 real-time PCR procedure need to be standardized: the European Sanco Concerted Action has devoted many efforts to this task in order to reduce interlabs variability and to implement highly reproducible assays. Moreover, we agree with Martinelli et al 1 that the level of minimal residual disease (MRD) observed during CR is critically determined by the timing of bone marrow sampling as well as by the chemotherapy protocol adopted (ie standard vs high doses of ARAC). In this connection, we have recently updated our preliminary results 3 of quantitative MRD after induction and consolidation in patients treated with standard doses of ARAC: after induction, 6/7 patients with 4100 copies of leukemic transcript relapsed compared to 2/12 with o100 copies (P ¼ TO THE EDITOR Cyclin D1 controls the early phase of cell cycle, and overexpression of cyclin D1 is associated with the pathogenesis of Bcell disorders such as mantle cell lymphoma (MCL), hairy cell leukemia (HCL) and multiple myeloma (MM). Several molecular mechanisms including the t(11;14)(q13;q32) could account for the activation of the CCND1 gene and the subsequent expression of cyclin D1. The human CCND1 gene encoding cyclin D1 spans 15 kb, includes five exons and four introns, and generates two major mRNAs of 1.7 and 4.4 kb that differ in their 3 0 -part, the 3 0 UTR region being absent in the shorter form. transcript could be present in t(11;14)(q13;q32)-bearing B-malignancies (Karpas 620) in good correlation with a previous report, 3 and also in cell lines harboring either an insertion of a switch region (U266) or a trisomy of chromosome 11 (NCI H929 and RPMI 8226). 4 There is no correlation between the presence of form [b] transcript and the mechanism of gene activation, and the two alternative form 
